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ABSTRACT
Anti-angiogenic treatments targeting the vascular endothelial growth factor or 
its receptors have shown clinical benefits. However, impact on long-term survival 
remains limited. Solid tumors display an acidic microenvironment that profoundly 
influences their biology. Consequences of acidity on endothelial cells and anti-
angiogenic therapies remain poorly characterized and hence are the focus of this 
study. We found that exposing endothelial cells to acidic extracellular pH resulted in 
reduced cell proliferation and migration. Also, whereas VEGF increased endothelial cell 
proliferation and survival at pH 7.4, it had no effect at pH 6.4. Furthermore, in acidic 
conditions, stimulation of endothelial cells with VEGF did not result in activation of 
downstream signaling pathways such as AKT. At a molecular level, acidity significantly 
decreased the expression of VEGFR-2 by endothelial cells. Consequently, anti-
angiogenic therapies that target VEGFR-2 such as sunitinib and sorafenib failed to 
block endothelial cell proliferation in acidic conditions. In vivo, neutralizing tumor 
acidity with sodium bicarbonate increased the percentage of endothelial cells 
expressing VEGFR-2 in tumor xenografts. Furthermore, combining sodium bicarbonate 
with sunitinib provided stronger anti-cancer activity than either treatment alone. 
Histological analysis showed that sunitinib had a stronger anti-angiogenic effect 
when combined with sodium bicarbonate. Overall, our results show that endothelial 
cells prosper independently of VEGF in acidic conditions partly as a consequence of 
decreased VEGFR-2 expression. They further suggest that strategies aiming to raise 
intratumoral pH can improve the efficacy of anti-VEGF treatments.
INTRODUCTION
Targeting the formation of new blood vessels in 
tumors has shown clinical benefits in cancer patients 
[1, 2]. So far, most anti-angiogenic therapies have focused 
on the vascular endothelial growth factor (VEGF) and its 
receptors since they play a central role in angiogenesis [3]. 
Both antibodies targeting the soluble form of VEGF and 
small tyrosine kinase inhibitors of VEGF receptors have 
shown anti-tumor activity, yielding a significant increase 
in progression free survival in several types of cancer 
including advanced renal cell carcinoma [4, 5], advanced 
hepato-cellular carcinoma [6], and metastatic colorectal 
cancer [7]. The effect is however limited and tumors 
eventually escape the inhibition of VEGF signaling. In fact, 
tumors can use multiple angiogenic factors besides VEGF 
to promote tumor angiogenesis or switch to other modes 
of vascularization such as vascular mimicry [8]. Hence, 
resistances to anti-VEGF therapies have considerably 
limited their effectiveness. Identifying these resistance 
mechanisms will help design novel therapeutic approaches 
aiming to enhance efficacy of VEGF targeting therapies.
Tumor microenvironment is classically acid as a 
consequence of high rate of glucose metabolism and poor 
tumor perfusion [9]. Acidity offers tumor cells a growth 
advantage as, in contrast to other cell types present in 
the tumor microenvironment, cancer cells possess all the 
enzymatic machinery necessary to keep a physiological 
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intracellular pH in acidic conditions [10, 11]. In addition, 
acidity favors tumor progression by increasing tumor cell 
mobility, invasion and metastasis [12, 13]. Furthermore, 
acidity participates in tumor immune escape by promoting 
T cell anergy [14]. Besides, acidic pH affects the response 
of cancer cells to conventional therapies. For instance, 
it reduces the efficacy of weak base chemotherapies 
by reducing their cellular uptake [15, 16]. Moreover, it 
renders cancer cells resistant to radiotherapy [17].
Whereas the effect of low pH values on cancer cells 
have been well characterized, little is known about the 
influence of acidity on endothelial cells and particularly 
on anti-VEGF therapies. In this study, we show that acidic 
extracellular pH decreases endothelial cell proliferation 
and abolishes VEGF-induced endothelial cell responses. 
In addition, acidity decreases the expression of VEGFR-2 
by endothelial cells and consequently prevents the anti-
angiogenic effect of sunitinib and sorafenib, two small 
tyrosine kinase inhibitors of VEGFR-2. In vivo, treating 
tumor bearing mice with sodium bicarbonate to raise the 
tumor microenvironmental pH increases the percentage 
of blood vessels expressing VEGFR-2 and potentiates the 
anti-cancer effects of sunitinib.
RESULTS
Acidity reduces endothelial cell (EC) proliferation 
and migration
We first evaluated the consequences of exposing 
EC to extracellular acidity on cell functions that are 
relevant to angiogenesis including proliferation, migration 
and survival. EC exposed to extracellular acidity were 
either elongated or displayed a pancake like morphology 
compared to the cobblestone appearance of control 
EC (Figure 1A). Proliferation of EC was markedly 
reduced when EC were cultured in acidic conditions 
(Figure 1B). MTS proliferation assay showed a 64% and 
a 34% proliferation reduction when EC were cultured at 
pH 6.4 and 6.8 respectively, compared to EC cultured at 
pH 7.4 (p < 0.0001, n = 10). Similar results were obtained 
by cell counting (Figure 1C). Cell cycle analysis by flow 
cytometry showed that EC exposed to acidity displayed an 
increase in G1 phase cells associated with a decrease in S 
and G2/M phase cells. Of note, no changes in sub-G1 phase 
cells were observed (Figure 1D). Acidity also significantly 
decreased EC migration. As shown in Figure 1E, we found 
a 60% migration diminution when EC were cultured at pH 
6.4 compared to 7.4 (p < 0.05, n = 3) and a 32% reduction 
at pH 6.8 compared to 7.4 (p < 0.05, n = 3). In addition, 
EC cultured in acidic conditions were more resistent to 
serum starvation induced apoptosis (Figure 1F). Serum 
withdrawal resulted in 46% of cells undergoing apoptosis 
after 48 hours when cultured at pH 7.4 versus 34% when 
cultured at pH 6.4 (p < 0.05, n = 3). Finally, acidity did not 
modify EC sprouting and tubulogenesis (data not shown). 
Taken together these results illustrate that extracellular 
acidity significantly impacts on EC functions relevant to 
angiogenesis.
Besides providing oxygen and nutrients to tissues, 
EC also actively participate in inflammation by recruiting 
leucocytes into sites of inflammation. The process of 
recruitment requires the production of chemokines 
and induction of ICAM-1 and VCAM-1 on EC which 
is mediated by factors that activate NF-κB, including 
TNF-α [18]. We thus next investigated whether acidity 
interferes with the response of EC to pro-inflammatory 
stimuli. To test this, EC were exposed to physiological 
pH or acidity and stimulated with TNF-α. Surface 
expression of ICAM-1 and VCAM-1 and intra-cellular 
expression of the chemokine MCP-1 were determined 
by flow cytometry. We found that VCAM-1 was not 
expressed by resting EC cultured either in physiological 
or acidic conditions. Expression levels of ICAM-1 and 
MCP-1 were similar in both conditions. TNF-α increased 
the expression of ICAM-1, VCAM-1 and MCP-1 
similarly in EC exposed to acidity and in EC cultured at 
physiological pH (Supplementary Figure S1A–S1B). 
Acidity reduces VEGF-induced endothelial cell 
responses
VEGF acts as a major pro-angiogenic factor in part 
by inducing endothelial cell proliferation and survival 
[19]. Thus, we next wished to examine if acidity affects 
VEGF-induced endothelial cell responses. EC were 
exposed to acidic pH for 12 hours before stimulation 
with VEGF and cell proliferation was determined after 
48 hours by MTS proliferation assay. As expected we 
found that VEGF increased EC proliferation by 32% 
(p < 0.0001) under physiological pH (Figure 2A). This 
effect was however lost when EC were cultured at pH 
6.4. Similar results were obtained by cell counting 
(Figure 2B). Furthermore, VEGF protecting effect against 
serum starvation induced apoptosis was abolished when 
EC were cultured at pH 6.4. At pH 7.4, in serum starvation 
conditions for 48 hours, 45% of EC underwent apoptosis 
versus 20% in the presence of VEGF (p < 0.05). In 
contrast, in acidic conditions, 32% of EC were apoptotic 
compared to 31% in the presence of VEGF (Figure 2C). 
Upon binding to its receptor VEGFR-2, VEGF 
triggers various signaling pathways. Among the different 
proteins activated by VEGFR-2-VEGF interaction, AKT 
and MAPK regulate EC proliferation [20–22]. We thus 
tested the ability of VEGF to activate AKT and MAPK 
in EC exposed to physiological or acidic pH. In Western 
blot, we found that VEGF increased AKT and MAPK 
phosphorylation at pH 7.4. This effect was however absent 
in EC cultured at pH 6.4 (Figure 2D).
Finally, to rule out that the lack of VEGF effects 
in acidic conditions was not due to VEGF inactivation 
by acidity, we set up the following experiment. EC were 
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cultured at pH 7.4 or 6.4. After 24 hours of incubation, 
EC were collected and cultured for an additional 
24 hours at pH 7.4 in the presence or not of VEGF. EC 
proliferation was then determined by MTS proliferation 
assay (Supplementary Figure S2A). We found that, as 
expected, VEGF increased the proliferation of EC that 
were cultured at pH 7.4. In contrast, VEGF had no effect 
on EC that were pre-exposed to pH 6.4 (Supplementary 
Figure S2B). Using the same experimental setting, we also 
investigated the protective effect of VEGF against serum 
starvation induced apoptosis. Similarly to what we found 
for EC proliferation, we observed that, whereas VEGF 
reduced the apoptosis rate of EC cultured at pH 7.4, it had 
no protective effect on EC that were pre-exposed to pH 6.4 
(Supplementary Figure S2C). 
Acidity reduces VEGFR-2 expression by EC
To gain insight into the mechanisms responsible 
for the loss of effect of VEGF in acidic conditions, we 
determined the level of expression of VEGF receptors by 
EC. VEGF possesses three major receptors VEGFR-1, 
VEGFR-2 and VEGFR-3, with VEGFR-3 acting mostly 
on lymphatic endothelial cells [23]. Using Western 
blot, we found that EC cultured in acidic conditions 
significantly reduced the expression of VEGFR-2. The 
reduction was apparent at pH 6.8 and maximal at pH 6.4 
(Figure 3A). Decreased expression of VEGFR-2 took 
already place after 4 hours of EC exposure to pH 6.4 
(Figure 3B). In contrast, acidity did not alter the expression 
of VEGFR-1 (Figure 3B). The loss of VEGFR-2 
expression was reversible; however, EC required 
48 hours at pH 7.4 to reincrease their levels of VEGFR-2 
(Figure 3C). To clarify the mechanism implicated in the 
reduction of VEGFR-2 expression induced by acidity, 
we determined VEGFR-2 mRNA level using real-time 
PCR. We found that VEGFR-2 mRNA was significantly 
reduced in EC exposed to pH 6.4 compared to pH 7.4 
(Figure 3D). We further investigated the effects of 
acidic pH on VEGFR-2 degradation by treating EC with 
Figure 1: Acidity reduces endothelial cell proliferation and migration. (A) Representative images of endothelial cells exposed to 
cultured medium buffered to pH 7.4, 6.8 or 6.4 for 48 hours. (B) MTS proliferation assay of EC cultured in medium buffered to the indicated 
pH for 48 hours. Results are expressed as mean absorbance at 490 nm of 10 independent experiments ± 1 SD. *p < 0.0001, Student’s t-test, 
compared to EC cultured at pH 7.4. (C) Endothelial cell count of EC cultured at the indicated pH for 48 hours. Dashed line represents 
the number of EC at the beginning of the experiments. Results are expressed as mean cell count ± 1 SD of 10 independent experiments. 
*p < 0.0001, Student’s t-test, compared to EC cultured at pH 7.4. (D) Cell cycle analysis using flow cytometry of endothelial cells treated as in 
panel a. One of three similar experiments is shown. (E) Migration assay of EC treated as in panel a. Results are expressed as mean cell count 
± 1 SD per three fields at high power magnification (× 400). *p < 0.05, Student’s t-test, compared to EC cultured at pH 7.4. (F) Percentage 
of EC undergoing apoptosis following the withdrawal of serum and cultured at the indicated pH for 48 hours. Results are expressed as mean 
apoptosis percentage ± 1 SD of three independent experiments. *p < 0.05, Student’s t-test, compared to EC cultured at pH 7.4.
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cycloheximide to block protein synthesis. Low pH had 
no significant effects on VEGFR-2 degradation, as in 
both, acidic and physiological pH, VEGFR-2 was mostly 
degraded after two hours of treatment (Figure 3E).
We further investigated whether the effect of acidity 
was specific for VEGFR-2 or whether it also affected the 
expression of other molecules implicated in angiogenesis, 
including FGFR-1, Tie-2, CD31 or αvβ3 integrin. Using 
flow cytometry, we found that acidity did not change the 
expression of CD31 and αvβ3 integrin (Supplementary 
Figure S3A). Furthermore, we observed that acidity did 
not alter the expression levels of FGFR-1 and Tie-2 as 
evidenced by Western blot (Supplementary Figure S3B). 
All together these data suggest that acidity specifically 
down-regulates the expression of VEGFR-2 in EC.
Acidity reduces the anti-proliferative efficacy of 
anti-VEGF therapies in vitro
We next hypothesized that since VEGFR-2 
expression is reduced in EC exposed to pH 6.4, therapies 
that target VEGFR-2 would lose their efficacy in acidic 
conditions. To test this, EC were cultured at pH 7.4 or 
6.4 and treated with sorafenib or sunitinib, two small 
molecule receptor tyrosine kinase inhibitors targeting 
VEGFR-2 [24, 25]. MTS proliferation assay performed 
after 48 hours of treatment revealed that sorafenib and 
sunitinib significantly reduced EC proliferation at pH 
7.4 (Figure 4A). We found 17% and 68% proliferation 
reduction by sorafenib and 23% and 71% proliferation 
reduction by sunitinib respectively at doses of 1 and 
10 μM compared to untreated EC (p < 0.0001). In contrast, 
no significant changes of proliferation were found when 
EC were exposed to pH 6.4 (Figure 4A). Similar results 
were obtained by cell counting (Figure 4B).
To exclude that the loss of antiproliferative effects 
of sorafenib and sunitinib in acidic conditions being due to 
their inactivation by acidity, we prexposed EC for 24 hours 
to culture medium buffered to pH 6.4 and subsequently 
treated EC and performed the proliferation assay at pH 7.4 
(Supplementary Figure S4A). According to our Western 
blot analysis, VEGFR-2 expression is reduced in acidic 
conditions after 24 hours and its expression following 
restoration to physiological pH needs more than 24 hours 
(Figure 3C). In this experimental setting, we found that 
sorafenib and sunitinib did not reduce EC proliferation 
Figure 2: VEGF-mediated EC responses are inhibited by acidity. (A) MTS proliferation assay of EC cultured at the indicated pH 
in presence or not of VEGF (10 ng/ml) for 48 hours. Results are expressed as mean absorbance at 490 nm of 10 independent experiments 
± 1 SD. *p < 0.0001, Student’s t-test, compared to control EC cultured at pH 7.4. (B) Endothelial cell count of EC cultured at the indicated 
pH for 48 hours stimulated or not with VEGF (10 ng/ml). Results are expressed as mean cell count ± 1 SD of 10 independent experiments. 
*p < 0.0001, Student’s t-test, compared to control EC cultured at pH 7.4. (C) Percentage of EC undergoing apoptosis following the 
withdrawal of serum and cultured at the indicated pH for 48 hours ± VEGF stimulation (10 ng/ml). Results are expressed as mean apoptosis 
percentage ± 1 SD of three independent experiments. *p < 0.05, Student’s t-test, compared to control EC cultured at pH 7.4. (D) EC cultured 
at the indicated pH for 24 hours and subsequently stimulated or not with VEGF (10 ng/ml) for one hour. Cell lysates were prepared and 
analyzed by Western blot with the indicated antibodies. Densitometric values of the ratio of phosphorylated protein to total protein are listed 
below each blots.
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when EC were pre-exposed to pH 6.4, hence ruling out 
that the loss of activity in acidic conditions did result from 
their inactivation by acidity (Supplementary Figure S4B). 
We further investigated whether the reduced 
anti-proliferative efficacy of sorafenib and sunitinib 
on EC cultured in acidic conditions can be reversed 
by re-exposing EC to physiological pH. To test this, 
EC were cultured at pH 6.4 for 24 hours followed 
by 48 hours culture at pH 7.4. At that time EC were 
collected and plated for a proliferation assay performed 
in the presence or absence of sorafenib or sunitinib 
(Figure 4C). We chose 48 hours restoration at 
physiological pH as it is the time required for EC to re-
express VEGFR-2 (Figure 3C). We observed that the 
proliferation rate of EC that were exposed to acidity 
was restored following exposure to pH 7.4. We further 
found that sorafenib and sunitinib significantly reduced 
EC proliferation following restoration of pH 7.4 for 
Figure 3: Acidity induces a reversible decrease of VEGFR-2 expression by EC. (A) EC were cultured at the indicated pH for 
24 hours. Cell lysates were analyzed by Western blot for VEGFR-2 and actin expression. Densitometric values of the ratio of VEGFR-2 
to actin are listed below the blots. (B) EC were cultured at pH 6.4 for the indicated hours. Cell lysates were analyzed by Western blot for 
VEGFR-2, VEGFR-1 and actin expression. Densitometric values of the ratio of VEGFR-2 to actin and VGFR-1 to actin are listed below 
each blots. (C) EC were cultured for 24 hours at pH 6.4 followed by restoration at pH 7.4 for 24 and 48 hours. Cell lysates were analyzed 
by Western blot for VEGFR-2 and actin expression. Densitometric values of the ratio of VEGFR-2 to actin are listed below the blots. 
(D) EC were exposed to pH 6.4 or physiological pH for 6 hours. Total mRNA was extracted and tested for VEGFR-2 levels and cyclophilin 
as a control by real-time PCR. Bar charts represent mean, error bars represent SD. *p < 0.05, Student’s t-test, compared to EC cultured at pH 
7.4. (E) EC were cultured at pH 7.4 or 6.4 for the indicated times in the presence of cycloheximide (CHX; 10 μM). Cell lysates were analyzed 
by Western blot for VEGFR-2 and actin expression. Densitometric values of the ratio of VEGFR-2 to actin are listed below the blots.
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48 hours (Figure 4D). Altogether these data suggest that 
acidity reduces the anti-proliferative efficacy of sorafenib 
and sunitinib. They further suggest that maintaining a 
physiological pH is necessary to maintain their efficacy.
Sodium bicarbonate potentiates the anti-cancer 
efficacy of sunitinib in vivo
Our in vitro observations suggest that acidity 
reduces the sensitivity of EC to sunitinib and sorafenib by 
reducing the expression of VEGFR-2. To next investigate 
the relevance of our findings in vivo, we hypothesized that 
increasing the intra-tumoral pH would increase VEGFR-2 
on blood vessels and hence potentiate the anti-angiogenic 
efficacy of anti-VEGFR-2 therapies. Previous reports 
demonstrated that the acidic extracellular pH of tumors 
can be safely increased by sodium bicarbonate in tumor 
xenografts [26]. We thus grew HT29 colon cancer cell 
tumor xenografts in nude mice and treated them with 
sodium bicarbonate. Following tumor harvesting dual 
immunofluorescence staining for CD31 and VEGFR-2 
was performed to determine VEGFR-2 expression on 
CD31 blood vessels. We found that 71.6% of CD31 
blood vessels expressed VEGFR-2 in untreated mice 
(Figure 5A–5B). The percentage rose to 93.9% when 
mice received sodium bicarbonate (p < 0.05 compared to 
untreated mice).
We next determined whether sodium bicarbonate 
could increase the anti-angiogenic and anti-tumor efficacy 
of sunitinib. To support this, we hypothesized that since 
the majority of blood vessels in tumor xenografts exposed 
to sodium bicarbonate are VEGFR-2 positive, blood 
Figure 4: Acidity decreases the anti-proliferative efficacy of sorafenib and sunitinib. (A) MTS proliferation assay of EC 
cultured at the indicated pH in presence or not of sorafenib (1 or 10 µM) or sunitinib (1 or 10 µM) for 48 hours. Results are expressed 
as mean absorbance at 490 nm of 10 independent experiments ± 1 SD. *p < 0.0001, Student’s t-test, compared to control EC cultured at 
pH 7.4. (B) Endothelial cell count of EC cultured at the indicated pH for 48 hours in presence or not of sorafenib (1 or 10 µM) or sunitinib 
(1 or 10 µM). Results are expressed as mean cell count ± 1 SD of 10 independent experiments. *p < 0.0001, Student’s t-test, compared 
to control EC cultured at pH 7.4. (C) Experimental set-up of the experiment presented in panel d. EC were exposed to pH 7.4 or 6.4 for 
24 hours followed by restoration of pH 7.4 for 48 hours. EC were subsequently collected and plated for a 24 hour proliferation assay at pH 7.4 
in presence or not of sunitinib (1 µM) or sorafenib (1 µM). (D) MTS proliferation assay of EC processed as described in panel c. Results are 
expressed as mean absorbance at 490 nm of triplicates ± 1 SD. *p < 0.05, Student’s t-test, compared to control EC cultured at pH 7.4 or 6.4. 
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vessels would be more sensitive to anti-VEGFR-2 therapy. 
To test this, mice bearing HT29 tumor xenografts were 
randomized into four treatment groups; vehicle, sodium 
bicarbonate, sunitinib, sodium bicarbonate and sunitinib. 
We found that tumor xenografts grew significantly slower 
in the sodium bicarbonate and sunitinib treatment groups. 
Combining sodium bicarbonate with sunitinib resulted in 
a stronger anti-cancer activity than either treatment alone 
(Figure 6A). Similar results were obtained in MC-38 tumor 
allografts (Figure 6B). Histological analysis revealed that 
combining sodium bicarbonate with sunitinib significantly 
decreased the number of blood vessels (87%) compared 
to sunitinib alone (48%) (Figure 6C). This was associated 
with increased necrosis (13.4 fold increase compared to 
vehicle, 1.6 fold increase compared to bicarbonate and 1.4 
fold increase compared to sunitinib) (Figure 6D).
DISCUSSION
Anti-angiogenic therapies are one of the most 
prescribed treatments in oncology. Indeed, up to ten drugs 
that target VEGF or its receptors have now been approved 
in cancer therapy [27]. However, to date, the anti-cancer 
efficacy of these compounds is limited and high effort 
is needed to improve their efficacy. In the present work, 
we have shown that acidity dampens the efficacy of 
anti-VEGF treatments. In vitro, acidic pH considerably 
reduced VEGF-mediated endothelial cell responses, 
suggesting that in acidic conditions endothelial cells 
prosper independently of VEGF. Accordingly, we found 
that low pH values significantly reduced the expression 
of VEGFR-2 by EC. In vivo, buffering tumor acidity 
with sodium bicarbonate increased the number of CD31/
VEGFR-2 positive blood vessels in tumor xenograft and 
potentiated the anti-cancer efficacy of sunitinib. Hence, 
sodium bicarbonate might improve the efficacy of 
sunitinib by increasing the number of blood vessels that 
express VEGFR-2. 
Tumor acidity profoundly influences the biology 
of tumors [10]. It affects cancer cells by increasing 
their motility and invasiveness and reduces the 
response of cancer cells to radiotherapy and weak base 
chemotherapies. Furthermore, acidity also modulates the 
tumor microenvironment by favoring T-cell anergy and 
hence promoting tumor immune escape [14]. Accordingly, 
the anti-tumor efficacy of immunotherapies is increased 
following the neutralization of tumor acidity [28]. Our 
study further highlights acidity as a factor that influences 
Figure 5: Sodium bicarbonate increases the percentage of VEGFR-2 positive blood vessels in HT29 tumor xenografts. 
(A) Mean percentage ± 1 SD of VEGFR-2 positive blood vessels in HT29 tumor xenografts grown in nude mice left untreated (vehicle) 
or receiving sodium bicarbonate in the drinking water (bicarbonate; 200 mmol/L). (B) Dual immunofluorescent staining for CD31 (red) 
and VEGFR-2 (green) in HT29 tumor xenografts harvested from nude mice that were untreated (vehicle) or received sodium bicarbonate 
(bicarbonate). Arrows: example of CD31 positive, VEGFR-2 negative blood vessels. Scale bars, 50 μM.
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tumor angiogenesis. Indeed, we observed that acidity 
decreased endothelial cell proliferation and migration 
suggesting that acidity slows the process of angiogenesis. 
Accordingly we found that sodium bicarbonate 
significantly increased the number of blood vessels 
in tumor xenografts (Figure 6B). Consistent with our 
observations, it was reported in the rat aortic ring model 
that acidity induced a marked delay in microvascular 
growth [29]. Also, acidity delayed migration of endothelial 
cells in irradiated wounds [30]. 
EC show heterogeneity in structure and function and 
accordingly protein expression differs significantly [31]. 
For instance, the expression of VEGFR-2 or Tie-2 by 
tumor endothelial cells varies in tumors [32, 33]. Similarly, 
we found that VEGFR-2 was not expressed by every tumor 
blood vessel (Figure 5A). The therapeutic consequence of 
Figure 6: Sodium bicarbonate potentiates the anti-angiogenic efficacy of sunitinib. (A) HT29 xenograft growth curves 
for treatments with vehicle, sunitinib (40 mg/kg p.o.), sodium bicarbonate (200 mmol/L in the drinking water) or a combination of both. 
*p < 0.0001, n = 5/group, Two-way ANOVA. (B) MC-38 allograft growth curves for treatments with vehicle, sunitinib (40 mg/kg p.o.), 
sodium bicarbonate (200 mmol/L in the drinking water) or a combination of both. * p < 0.0001, n = 5/group, Two-way ANOVA. (C) Tumor 
vasculature in HT29 xenografts was analyzed by counting CD31 positive vessels in 10 representative sections of 500 × 500 μm for three 
different tumors of each treatment group. Scale bars, 100 μm. Bar charts represent mean, error bars represent SD. **p < 0.0001, *p < 0.05, 
One-way ANOVA. (D) Tumor necrosis in HT29 xenografts (light pink stained surface in H&E) was evaluated in each treatment group in 
10 representative sections of 3368 × 2668μm for three different tumors. Scale bars, 500 μm. Bar charts represent mean, error bars represent 
SD. **p < 0.0001, One-way ANOVA.
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such heterogeneity remains however poorly characterized. 
Whilst it is known that tumors displaying higher degree 
of Tie-2 negative blood vessels respond less to anti-Tie2 
therapy [32], little is known about the responsiveness of 
VEGFR-2 negative blood vessels to anti-VEGF treatment. 
Here, we find that increased numbers of VEGFR-2 
expressing tumor blood vessels were associated with 
increased efficacy of sunitinib suggesting that acidity 
lessens the efficacy of anti-VEGF therapies by reducing 
VEGFR-2 expression. Of note, several resistances to anti-
angiogenic drugs have been identified including escape 
via different modes of vascularization and secretion 
of multiple pro-angiogenic factors [34]. Since acidity 
profoundly affects the phenotype of cancer cells and cells 
present in the tumor microenvironment, several other 
mechanisms, not limited to an increased expression of 
VEGFR-2 by tumor EC, are expected to participate in the 
process of resistance to anti-VEGF therapies. 
Recent studies have shown that sodium bicarbonate 
displays anti-cancer activity in different mouse models 
[35]. Sodium bicarbonate reduced the number and 
size of metastases in a breast tumor xenograft model 
[26]. In addition, it also reduced the formation of liver 
metastasis following cancer cell injection into the tail 
vein. Contrasting results exist on the effect of sodium 
bicarbonate on the growth of primary tumor in mice 
models. In human tumor xenografts, sodium bicarbonate 
reduced the growth of HCT-116 colon tumors but had 
no effect on the growth of MDA-MB231 breast tumors 
[26, 36]. Similarly, in immune competent C57BL/6 mice, 
bicarbonate therapy did not affect the growth rate of B16 
melanoma tumors but significantly reduced the growth of 
Yumm1.1 melanoma [28]. Finally, in a transgenic model 
of prostate cancer, bicarbonate prevented the development 
of tumors [37]. In our study, we observed that sodium 
bicarbonate significantly reduced the growth rate of HT29 
tumor xenografts and MC-38 tumor allografts. Hence, 
future studies are needed to fully characterize the anti-
cancer efficacy of sodium bicarbonate and identify the 
molecular mechanisms responsible for these effects. 
We found that sodium bicarbonate treatment 
increased VEGFR-2 expression and mean vessel density 
but reduced tumor growth. This was also associated with 
increased tumor necrosis. Such paradigm was previously 
reported in other experimental settings such as following 
DLL-4-Notch blockade and was due to immature, non 
functional blood vessels [38, 39]. In addition, other 
molecular mechanisms could contribute to the anti-cancer 
effects of sodium bicarbonate. It is well established that 
acidity impairs the function of other cell types present 
in the tumor microenvironment including inflammatory/
immune cells. For instance, acidity increases the response 
of tumor promoting macrophages [40]. Also acidity 
induces anergy of tumor infiltrating T cells and reduces 
the activity of NK cells [14, 41]. Therefore, sodium 
bicarbonate could favor anti-tumor responses of immune 
cells by at least two mechanisms. Firstly, the augmented 
mean vascular density induced by sodium bicarbonate 
could increase the recruitment of these cells into the tumor 
and secondly buffering tumor acidity could increase their 
anti-tumor activity. Clearly additional studies are needed 
to fully characterize the mechanisms by which sodium 
bicarbonate reduces tumor growth.
The use of sodium bicarbonate in human patients 
might be associated with toxicity and needs to be evaluated. 
However, other means exist to target tumor acidity. 
For instance, emerging evidence have demonstrated 
the contribution of the carbonic anhydrase IX (CAIX) 
in creating an acidic tumor microenvironment [42]. 
Interestingly, it was shown that targeting CAIX enhances 
the efficacy of bevacizumab, a VEGF targeting antibody, 
further underlining a possible role for tumor acidity in 
decreasing the effects of anti-angiogenic drugs [43]. 
Several specific CAIX inhibitors have now been developed 
and are entering phase I clinical trials and thus warrant to 
be tested in combination with anti-angiogenic therapies 
[44]. Beside CAIX, many other proteins participate in 
the regulation of pH in tumors including V-ATPase, 
monocarboxylate transporters, Na+/H+ exchangers which 
could also be easily targeted [10, 11, 45].
In conclusion, our results show that acidity reduces 
VEGF-mediated endothelial cell responses in vitro and 
accordingly diminishes the anti-angiogenic efficacy of 
anti-VEGF therapies. They further provide a rationale to 
associate anti-angiogenic treatments with therapies aiming 
to increase intra-tumoral pH in clinical trials.
MATERIALS AND METHODS
Antibodies and reagents
Sunitinib and sorafenib were from LC Laboratories 
(Woburn, MA, USA). Sodium bicarbonate and HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
were from Sigma-Aldrich. Recombinant human VEGF 
was from Peprotech (#100-20-10). Cycloheximide 
was purchased from Santa Cruz biotechnology (#SC-
3508). For Western blot analysis, the following primary 
antibodies and concentrations were used: anti-phospho-
Akt antibody (1:500) (#4060; Cell Signaling Technology), 
anti-Akt antibody (1:1000) (#2920; Cell Signaling 
Technology), anti-VEGFR-2 antibody (1:1000) (#2479; 
Cell Signaling Technology), anti-VEGFR-1 (1:500) (#sc-
316; Santa Cruz biotechnology), anti-β-actin antibody 
(1:5000) (#A2228; Sigma Aldrich), anti-Tie-2 antibody 
(1:500) (#MAB313; R&D systems) and anti-FGFR-1 
antibody (1:1000) (#sc-121; Santa Cruz Biotechnology). 
Immunohistochemical staining were performed with 
anti-CD31 antibody (#Rb-10333-PO; Thermo Scientific). 
For immunofluorescence anti-CD31 (1:50) (# 553370; 
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BD Pharmigen) and anti-VEGFR-2 antibody (1:50) 
(#2479; Cell Signaling Technology) were used. For 
flow cytometry, the following antibodies and dilutions 
were used: anti-CD31 (1:100) (#17-0319; eBioscience), 
anti-avb3 integrin (1:100) (MAB1976; Millipore), anti-
VCAM-1(1:100) (#12-1069; eBioscience), anti-ICAM-1 
(1:100) (#12-0549; eBioscience) and anti-MCP-1 (1:100) 
(#12-7099; eBioscience).
Cell culture
Human umbilical vein endothelial cells (HUVEC) 
were purchased from Lonza and cultured in EBM 
complete medium. HUVEC were used for the experiments 
between passages 2 and 5. HT29 human colon cancer 
cells were obtained from ATCC and murine colon 
adenocarcinoma cell line MC-38 was kindly provided 
by Dr. Jeffrey Schlom (National Cancer Institute, NIH) 
[46]. Both cell lines were cultured in Dulbecco’s Modified 
Eagle’s Medium - high glucose (DMEM) (Sigma-Aldrich, 
Buchs, Switzerland) supplemented with 10% FBS and 1% 
streptomycin/penicillin. 
Proliferation assay
EC were plated on 96 well plates (Costar) at 10’000 
cells per well and cultured in EBM complete medium. 
Twelve hours later, medium was removed and replaced 
by EBM complete medium buffered to pH 7.4, 6.8 or 6.4. 
Cellular proliferation was monitored after 48 hours with 
CellTiter 96® AQueousOne Solution (Promega Corporation) 
colorimetric assay by following the manufacturer’s 
instructions. Results are expressed as mean absorbance at 
490 nm of 10 independent experiments ± 1 SD.
Cell cycle analysis
EC were cultured in medium buffered to pH 7.4, 
6.8 or 6.4 for 48 hours. Attached and floating EC were 
then collected and fixed in 95% ethanol overnight. Cells 
were washed twice in phosphate buffered saline (PBS) 
and subsequently incubated in PBS containing propidium 
iodide (50 μg/ml) and RNase A (100 μg/ml). Cell cycle 
was analyzed by fluorescence-activated cell sorter using 
Cellquest software (BD Biosciences). For apoptosis assay, 
EC were cultured in serum free medium buffered to pH 
7.4, 6.8 or 6.4 for 48 hours and subsequently analyzed as 
above.
Cell count
One hundred thousand EC were plated in six well 
plates coated with gelatin 0.5%. After attachement, 
medium was replaced with cell medium buffered at 
pH 7.4, 6.8 or 6.4 for 48 hours. Subsequently, adherent 
cells were collected and trypan-blue negative cells were 
counted using a Neubauer hemocytometer. Results are 
expressed as mean cell count ± 1 SD of 10 independent 
experiments.
Migration assay
Migration assays were performed as previously 
described [47]. Briefly, the lower surface of an 8 µm pores 
Transwell filter was coated with fibronectin (10 mg/ml) 
for two hours and subsequently blocked with 1% bovine 
serum albumin for one additional hour. Endothelial cells 
were exposed to the indicated pH for 48 hours, collected 
and added to the upper chamber of the transwell in serum 
free medium (4 × 104 endothelial cells per transwell). After 
3 hours filters were fixed in 2% paraformaldehyde and 
stained in 0.5% crystal violet. Migrated cells were counted 
on the lower surface of the filter by light microscopy in 
three high-power fields. Results are expressed as mean cell 
count ± 1 SD per three fields at high power magnification 
(× 400).
Flow cytometry
EC were cultured for 24 hours at pH 7.4 or 6.4. 
For some experiments, EC were subsequently stimulated 
or not with TNF-α (10ng/ml) for twelve hours. EC 
were collected, rinsed and incubated in PBS with APC-
conjugated antibody to CD31 (#17-0319; eBioscience), 
FITC-conjugated antibody to avb3 integrin (MAB1976; 
Millipore), phycoerythrin-conjugated antibody to VCAM-
1 (#12-1069; eBioscience) or ICAM-1 (#12-0549; 
eBioscience) or with the labeled matched IgG isotype 
as control for 45 minutes at 4°C. Stained cells were 
analyzed in a FACSCalibur using CellQuest software 
(Becton Dickinson). To measure intracellular MCP-1 
production, GolgiStop (#554715; BD Bioscience) was 
added to the cell culture medium 3 hours before analysis. 
Cells were fixed/permeabilized in Cytofix/Cytoperm 
solution (#554715; BD Bioscience) following the 
manufacturer’s instructions. Fixed cells were incubated 
with phycoerythrin-conjugated antibody to MCP-1 (#12-
7099; eBioscience) or phycoerythrin-labeled matched IgG 
isotype as control for 45 minutes at 4°C and analyzed as 
above.
Western blot analysis
EC were plated in 6 well plates at 200’000 cells 
per well and cultured in EBM medium adjusted to 
different pH using HEPES. For some experiments, EC 
were cultured at the indicated pH for 24 hours followed 
by a one hour stimulation with VEGF (10 ng/ml). Cells 
were lysed in RIPA buffer. Protein concentrations were 
measured using BCA Assay (Pierce, Rockford, IL, USA). 
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Equal amounts of protein (20 μg) were separated on 
4–12% polyacrylamide gel and subsequently transferred 
to a polyvinylidene difluoride membrane (Millipore, 
Schaffhausen, Switzerland). Membranes were blocked 
with Odyssey blocking buffer (LI-COR Biosciences, 
Lincoln, NE, USA) and immunoblotted with primary 
antibodies followed by infrared secondary antibodies. 
Bands from immunoreactive proteins were visualized 
by an Odyssey infrared imaging system (LI-COR 
Biosciences). Densitometric analysis was performed 
using ImageJ software. Density values of phosphorylated 
proteins were normalized to total protein for each sample. 
In some experiment, density values of protein were 
normalized to actin. Unstimulated cells were given a value 
of 1.0, and ratios in all other samples were normalized to 
this value. Densitometric values are listed below each blot.
Real-time PCR
RNA extraction was performed using RNeasy 
Mini Kit from Qiagen by following the manufacturer’s 
instructions. We used 500 ng of RNA for reverse 
transcription with SuperScript II Reverse Transcriptase 
from ThermoFisher Scientific. The resulting cDNA 
was used for qRT-PCR (Rotor-Gene Q from Qiagen). 
qRT-PCR were set up in triplicates with KAPA SYBR 
FAST qPCR Kit Master Mix Universal KK4602 from 
Kapa Biosystems. The relative expression levels of the 
target gene mRNAs were calculated by the comparative 
CT method (relative expression = 2
−ΔCT) using cyclophilin 
as an internal control. Primer sequences were: human 
VEGFR2 forward ATC CCT GTG GAT CTG AAA CG, 
human VEGFR2 reverse CCA AGA ACT CCA TGC CCT 
TA, human VEGFA forward CCT CCG AAA CCA TGA 
ACT TT, human VEGFA reverse ATG ATT CTG CCC 
TCC TCC TT, human cyclophilin forward ACC GTG TTC 
TTC GAC ATT GC, human cyclophilin reverse TTA TGG 
CGT GTG AAG TCA CC.
Immunohistochemistry
Xenografts were fixed in 4% formaline overnight, 
dehydrated with ethanol and paraffin-embedded. Sections 
of 3μm were obtained using MICROM HM 355S 
microtome (Thermo Scientific, Ecublens, Switzerland), 
and tissue sections were mounted on Superfrost Plus 
slides (Thermo Scientific, Ecublens, Switzerland). Slides 
were then deparaffinized and rehydrated with xylol and 
alcohol. After antigen retrieval (citrate pH 6.0 or TRIS/
EDTA pH 9.0), sections were immunostained using anti-
CD31 primary antibody for 60 minutes and subsequently 
incubated with Dako EnVision HRP secondary antibody 
(Dako, Baar, Switzerland) for 30 minutes. In parallel, 
staining with haematoxylin and eosin were performed. 
One section from each xenograft tumor and three tumors 
for each condition were analyzed for each staining. 
Carl Zeiss Axioscope, AxioCam MRc and AxioVision 
40V 4.6.3.0 software (Carl Zeiss Vision Swiss AG, 
Feldbach, Switzerland) were used for image acquisition 
and processing. Histology analysis was performed by 
two researchers blinded to groupings. Blood vessel 
count was determined in 10 representative sections of 
500 × 500 μm for three different tumors of each treatment 
group. Percentage of tumor necrosis (light pink stained 
surface in H&E) were measured quantitatively using 
ImageJ 1.46r Threshold Colour Plugin by analyzing 
10 representative images of 3368 × 2668 μm for each 
condition in three different tumors. 
Immunofluorescence
Tumor samples were frozen in OCT compound 
(Tissue-Teck) on liquid nitrogen. Eight µm thick sections 
were cut on a cryostat. Slides were fixed in ice cold 
acetone for 5 minutes, washed three times for five minutes 
in PBS and blocked in 10% donkey serum for 10 minutes. 
Incubation with anti-CD31 (1:50) and anti-VEGFR-2 
(1:50) antibodies diluted in PBS/0.1% BSA was performed 
for 60 minutes. Subsequently, slides were washed three 
times for five minutes with PBS and incubated with 
donkey anti-rat 488 (1:500) and donkey anti-rabbit 
(1:500) secondary antibodies diluted in PBS/0.1% BSA for 
30 minutes. Following three washes with PBS, slides were 
incubated for 10 minutes with DAPI solution (1:3000) 
and coverslipped using DAKO fluorescence mounting 
medium (#S3023). Slides were visualized using an 
inverted fluorescence microscope (Axiovert, Zeiss) and 
photographs were taken using a Zeiss AxioCam camera. 
Three random fields at 200 × magnification per xenografts 
(n = 3/group) were taken and the percentage of CD31/
VEGFR-2 positive vessels was determined.
Mouse model
Animal experiments were in accordance with the 
Swiss federal animal regulations and approved by the 
local veterinary office. Female nude or female C57BL/6 
eight-week old mice were purchased from Janvier Labs 
(Saint Berthevin Cedex, France). Mice were randomized 
into different groups (n = 5/group; groups “vehicle” - 
“bicarbonate” - “sunitinib” - “bicarbonate and sunitinib”). 
HT29 (3 × 106) or MC-38 (1 × 106) cells were injected 
subcutaneously into the right flank. Sodium bicarbonate 
was added to the drinking water at a concentration of 
200 mmol/L, starting one day before cancer cell injection. 
Once the tumor xenografts reached a mean volume of 
25 mm3, mice were treated once daily with sunitinib 
(sunitinib 40 mg/kg p.o. diluted in 100 μl of 
carboxymethylcellulose 0.5%, NaCl 1.8%, Tween20 0.4% 
and ethahol 0.9% in distilled water, pH adjusted to 6.0) 
or vehicle (100 μl of carboxymethylcellulose 0.5%, NaCl 
1.8%, Tween20 0.4% and ethanol 0.9% in distilled water, 
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pH adjusted to 6.0). Tumor volumes were measured daily 
using a caliper and calculated with the formula V = A * 
B * C * π/6 where A is the length, B the width and C 
the height of the tumor. Animals were sacrificed once the 
biggest tumor of vehicle treated mice reached the size of 
1’000 mm3 (defined as interruption criterion according to 
veterinary recommendations). 
Statistics
Statistical analysis including Student’s t-test, One-
way ANOVA and Two-way ANOVA were carried out as 
appropriate using GraphPad Prism version 6.05.
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